

U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.5)		INTERNATIONAL APPLICATION NO. PCT/IL00/00185		ATTORNEY'S DOCKET NUMBER 110598			
17. <input checked="" type="checkbox"/> The following fees are submitted:  <b>Basic National fee (37 CFR 1.492(a)(1)-(5)):</b>  Search Report has been prepared by the EPO or JPO ....\$860.00  International preliminary examination fee paid to USPTO (37 CFR1.482) .....\$690.00  No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) .....\$710.00  Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO .....\$1,000.00  International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) .....\$ 100.00  <b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				CALCULATIONS		PTO USE ONLY	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input checked="" type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$			
Claims		Number Filed		Number Extra		Rate	
Total Claims		36- 20 =		16		X \$ 18.00	
Independent Claims		5- 3 =		2		X \$ 80.00	
Multiple dependent claim(s)(if applicable)				+ \$270.00		\$	
TOTAL OF ABOVE CALCULATIONS =				\$1,308.00			
Reduction by 1/2 for filing by small entity, if applicable.				-		\$654.00	
SUBTOTAL =				\$654.00			
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 month from the earliest claimed priority date (37 CFR 1.492(f)).				+		\$	
TOTAL NATIONAL FEE =				\$654.00			
				Amount to be refunded		\$	
				Charged		\$	
a. <input checked="" type="checkbox"/> Check No. <u>122909</u> in the amount of <u>\$654.00</u> to cover the above fees is enclosed.							
b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed.							
c. <input checked="" type="checkbox"/> The Director is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Deposit Account No. <u>15-0461</u> . A duplicate copy of this sheet is enclosed.							
<b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</b>							
SEND ALL CORRESPONDENCE TO: OLIFF & BERRIDGE, PLC P.O. Box 19928 Alexandria, Virginia 22320							
Date: <u>September 20, 2001</u>				NAME: <u>James A. Oliff</u> REGISTRATION NUMBER: <u>27,075</u>			
				NAME: <u>Thomas J. Pardini</u> REGISTRATION NUMBER: <u>30,411</u>			

1014 Rec'd ST/PTO 12 0 SEP 2001

(1390 REV. 5-93) US DEPT. OF COMMERCE PATENT & TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER 110598
<b>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371</b>		U.S. APPLICATION NO. (if known, sec 37 C.F.R.1.5)  <b>09/936922</b>
INTERNATIONAL APPLICATION NO. PCT/IL00/00185	INTERNATIONAL FILING DATE March 24, 2000	PRIORITY DATE CLAIMED March 25, 1999
TITLE OF INVENTION PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC GLYCEROPHOSPHATES AND ANALOGS THEREOF FOR PROMOTING NEURAL CELL DIFFERENTIATION		
APPLICANT FOR DO/EO/US Meir SHINITZKY		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.		
2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.		
3. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).		
4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.		
5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US)		
6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).		
7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made.		
8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).		
9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).		
10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).		
<b>Items 11. to 16. below concern other document(s) or information included:</b>		
11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.		
12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.		
13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.		
14. <input type="checkbox"/> A substitute specification.		
15. <input checked="" type="checkbox"/> Entitlement to small entity status is hereby asserted.		
16. <input checked="" type="checkbox"/> Other items or information: Submission of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)), Notification of the Recording of a Change.		

**PATENT APPLICATION**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of

Meir SHINITZKY

Attn: PCT Branch

Application No. U.S. National Stage of PCT/IL00/00185

Filed: September 20, 2001

Docket No.: 110598

For: PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC  
GLYCEROPHOSPHATES AND ANALOGS THEREOF FOR PROMOTING  
NEURAL CELL DIFFERENTIATION

**SUBMISSION OF THE ANNEXES TO THE  
INTERNATIONAL PRELIMINARY EXAMINATION REPORT**

Director of the U.S. Patent and Trademark Office  
Washington, D.C. 20231

Sir:

Attached hereto are the annexes to the International Preliminary Examination Report (Form PCT/IPEA/409). The attached translated material replaces the material in the claims.

Respectfully submitted,



James A. Oliff  
Registration No. 27,075

Thomas J. Pardini  
Registration No. 30,411

JAO:TJP/cmm

Date: September 20, 2001

**OLIFF & BERRIDGE, PLC**  
**P.O. Box 19928**  
**Alexandria, Virginia 22320**  
**Telephone: (703) 836-6400**

DEPOSIT ACCOUNT USE AUTHORIZATION Please grant any extension necessary for entry; Charge any fee due to our Deposit Account No. 15-0461
--